Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

Neurotherapy As a Catalyst in the Treatment of Fatigue in Breast Cancer Survivorship.

Pharmacologic and non-pharmacologic treatments for cancer-related fatigue (CRF) have produced mixed and often disappointing results. Treatment using the Flexyx Neurotherapy System (FNS), a novel variant of electroencephalograph biofeedback that involves minutely pulsed electromagnetic (EM) stimulation of brainwave functioning, was explored to determine utility for alleviating CRF in a 45-year-old woman who had debilitating fatigue with onset during chemotherapy for stage II infiltrating right breast cancer, who had been free of signs of disease for over five years, and who had been struggling to increase her activity level and engage in regular exercise without benefit. FNS was administered in 10 weekly sessions. Alleviation of fatigue and other potentially interrelated symptoms (cognitive clouding, sleep disturbance, pain, and negative mood/emotions) and overall greater activity level was sustained at six-month follow-up. Very low energy EM brainwave stimulation therapies such as FNS may contribute to an enlivening of drive to engage in greater energized activity.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app